Ozempic is a medicine prescribed for the treatment of adult patients with type 2 diabetes mellitus. Although in recent years Ozempic has been often prescribed “off-label” for weight loss, it is not currently approved for this indication.
Ozempic (semaglutide) is available as a single-patient-use pen for subcutaneous injection in the following strengths:
The active ingredient in Ozempic, semaglutide, is a GLP-1 receptor antagonist. It acts the same way as GLP-1 (a hormone produced in the gut). By increasing the amount of insulin released by the pancreas in response to food, semaglutide helps control blood glucose levels .
Ozempic (semaglutide) is currently approved in the USA, EU, Canada, Japan, and Australia for the treatment of type 2 diabetes.
Ozempic is not approved anywhere for use as a weight loss medication.